首页> 外国专利> COMPOUNDS USEFUL IN PAIN RELIEF WHICH CONTAIN METHYLENEAMINO AND OXY LINKING GROUPS, PROCESS FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS

COMPOUNDS USEFUL IN PAIN RELIEF WHICH CONTAIN METHYLENEAMINO AND OXY LINKING GROUPS, PROCESS FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS

机译:含亚甲基和氧连接基团的疼痛缓解化合物,制备它们的方法,包含它们的药物组合物及其在制备药物组合物中的用途

摘要

Pain relieving compounds of the formula wherein: A is an optionally substituted: phenyl, naphthyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidiyl, thienyl, thiazolyl, oxazolyl or thiadiazolyl having at least two adjacent ring carbon atoms; provided that 3103 ח' בטבת התשס" ב - December 23, 2001 the -CH(R3)N(R2)B-R1 and -OR4 groups are positioned in a 1,2-relationship to one another on ring carbon atoms and the ring atom positioned ortho or the OR4 linking group (and therefore in the 3-position relative to the -CHR3NR2-linking group) is not substituted; B is an optionally substituted: phenyl, pyridyl, thiazolyl, thienyl, thiadiazolyl, imidazolyl, pyrazinyl, pyridazinyl or pyrimidyl; R1 is positioned on ring B in a 1,3 or 1,4 relationship with the -CH(R3)N(R2)- linking group and is carboxy, carboxy (C1-3 alkyl, tetrazolyl, tetrazolyl C1-3 alkyl, tetronic acid, hydroxamic acid radical, sulphonic acid radical, or R4 is of the formula -CONRaRal wherein Ra is hydrogen or C1-6 alkyl and Ra1 is hydrogen, C1-6 alkyl (optionally substituted by halo, amino, C1-4 alkylamino, di-C1-4 alkylamino, hydroxy, nitro, cyano, trifluoromethyl, C1-4 alkoxy or C1-4 alkoxycarbonyl), C2-6 alkenyl (provided the double bond in not in the 1-position), C2-6 alknyl (provided the triple bond is not in the 1-position), carboxyphenyl, 5- or 6-membered heterocyclyl C1-3 alkyl, 5- or 6-membered heteroaryl C1-3 alkyl, 5- or 6-membered heterocyclyl, or 5- or 6-membered heteroaryl or Ra and Ral together with the amide nitrogen to which they are attached (NRaRal) form an amino acid residue or ester thereof, or R1 is of the formula -CONHSO2Rb wherein Rb is C1-6 alkyl (optionally substituted by halo, hydroxy, nitro, cyano, trifluoromethyl, C1-4 alkoxy, amino, C1-4 alkylamino, di-C1-4 alkylamino or C1-4 alkoxycarbonyl), C2-6 alkenyl (provided the double bond is not in the 1-position), C2-6 alkynyl (provided the triple bond is not in the 1-position), 5- or 6-membered heterocyclyl C1-3 alkyl, 5- or6-membered heteroaryl C1-3 alkyl, phenyl C1-3 alkyl, 5- or 6-membered heterocyclyl, 5- or 6-membered heteroaryl or phenyl; wherein any heterocyclyl or heteroaryl group in Ra1 is optionally substituted by halo, hydroxy, nitro, cyano, trifluoromethyl, C1-4 alkoxy or C1-4 alkoxycarbonyl and any phenyl, heterocyclyl or heteroaryl group in Rb is optionally substituted by halo, trifluoromethyl, nitro, hydroxy, amino, cyano C1-6 alkoxy, C1-6 alkylS(O)p- (p is 0, 1 or 2), C1-6 alkyl, carbamoyl, C1-4 alkylcarbamoyl, di(C1-4 alkyl) carbamoyl, C2-6 alkenyl, C2-6 alkynyl, C1-4 alkoxycarbonylamino, C1-4 alkanoylamino, C1-4 alkanoyl (N-C1-4 alkyl) amino, C1-4 alkanesulphonamido, benzenesulphonamido, aminosulphonyl, C1-4 alkylaminosulphonyl, di(C1-4 alkyl) aminosulphonyl, C1-4 alkoxycarbonyl, C1-4 alkanoyloxy, C1-6 alkanoyl, formyl C1-4 alkyl, hydroxyimino C1-6 alkyl, C1-4 alkoxyimino C1-6 alkyl or C1-6 alkylcarbamoylamino; or R1 is of the formula -SO2N(R!)R!l wherein R! is hydrogen or C1-4 alkyl and R!i is hydrogen or C1-4 alkyl; or R1 is of the formula (IA), (IB) or (IC); wherein X is CH or nitrogen, Y is oxygen or sulphur, Y( is oxygen or NRd and Z is CH2, NRd or oxygen provided that there is no more than one ring oxygen and there are at least two ring heteroatoms and wherein Rd is hydrogen or C1-4 alkyl; R2 is hydrogen, C1-6 alkyl, optionally substituted by hydroxy, cyano or trifluoromethyl, C2-6 alkenyl (provided the double bond is not in the 1-position). 3104 ח' בטבת התשס" ב - December 23, 2001
机译:下式的疼痛缓解化合物,其中:A是任选取代的:具有至少两个相邻的环碳原子的苯基,萘基,吡啶基,吡嗪基,哒嗪基,嘧啶基,噻吩基,噻唑基,恶唑基或噻二唑基;前提是2001年12月23日3103ח'בטבתהתשס“ב-CH(R3)N(R2)B-R1和-OR4基团在环碳原子和环上彼此成1,2-关系位于邻位或OR4连接基团(因此相对于-CHR3NR2-连接基团的3位)中的原子未被取代; B是可选取代的:苯基,吡啶基,噻唑基,噻吩基,噻二唑基,咪唑基,吡嗪基,哒嗪基或嘧啶基; R1与-CH(R3)N(R2)-连接基团成1,3或1,4关系位于B环上,且为羧基,羧基(C1-3烷基,四唑基,四唑基C1-3)烷基,tetronic酸,异羟肟酸基,磺酸基或R4具有式-CONRaRal,其中Ra为氢或C1-6烷基,且Ra1为氢,C1-6烷基(可选地被卤素,氨基,C1-4取代)烷基氨基,二-C1-4烷基氨基,羟基,硝基,氰基,三氟甲基,C1-4烷氧基或C1-4烷氧基羰基),C2-6烯基(前提是双键不在1位),C2-6烷基(假设三键不在1位),羧基苯基,5或6元杂环基C1-3烷基,5或6元杂芳基C1-3烷基,5 -或6-元杂环基,或5-或6-元杂芳基或Ra和Ral与它们所连接的酰胺氮(NRaRal)一起形成氨基酸残基或酯,或R1具有式-CONHSO2Rb,其中Rb是C1-6烷基(可选被卤素,羟基,硝基,氰基,三氟甲基,C1-4烷氧基,氨基,C1-4烷基氨基,二-C1-4烷基氨基或C1-4烷氧羰基取代),C2-6烯基( (前提是双键不在1位),C2-6炔基(前提是三键不在1位),5或6元杂环基C1-3烷基,5或6元杂芳基C1 -3烷基,苯基C 1-3烷基,5或6元杂环基,5或6元杂芳基或苯基;其中Ra1中的任何杂环基或杂芳基任选地被卤素,羟基,硝基,氰基,三氟甲基,C1-4烷氧基或C1-4烷氧基羰基取代,并且Rb中的任何苯基,杂环基或杂芳基任选地被卤素,三氟甲基,硝基取代,羟基,氨基,氰基C1-6烷氧基,C1-6烷基S(O)p-(p为0、1或2),C1-6烷基,氨基甲酰基,C1-4烷基氨基甲酰基,二(C1-4烷基)氨基甲酰基,C2-6烯基,C2-6炔基,C1-4烷氧羰基氨基,C1-4烷酰基氨基,C1-4烷酰基(N-C1-4烷基)氨基,C1-4烷磺酰胺基,苯磺酰胺基,氨基磺酰基,C1-4烷基氨基磺酰基,二(C1-4烷基)氨基磺酰基,C1-4烷氧基羰基,C1-4烷酰氧基,C1-6烷酰基,甲酰基C1-4烷基,羟基亚氨基C1-6烷基,C1-4烷氧基亚氨基C1-6烷基或C1-6烷基氨基甲酰基氨基;或R 1为式-SO 2 N(R 1)R 11,其中R 1为-。是氢或C 1-4烷基,R 1是氢或C 1-4烷基;或R 1为式(IA),(IB)或(IC);其中X为CH或氮,Y为氧或硫,Y(为氧或NRd,Z为CH2,NRd或氧,条件是不超过一个环氧且至少有两个环杂原子且其中Rd为氢或C1-4烷基; R2为氢,C1-6烷基,可任选被羟基,氰基或三氟甲基取代,C2-6链烯基(假设双键不在1位)。3104-'或-C1-4烷基。 2001年12月23日

著录项

  • 公开/公告号IL118664B

    专利类型

  • 公开/公告日2001-12-23

    原文格式PDF

  • 申请/专利权人 ASTRAZENECA UK LIMITED;SYNGENTA LIMITED;

    申请/专利号IL118664

  • 发明设计人

    申请日1996-06-16

  • 分类号C07C211/49;A61K31/13;A61K31/16;A61K31/275;A61P29/00;C07C215/68;C07C229/52;C07C237/40;C07C255/42;C07C259/10;C07C311/51;C07D213/60;C07D233/66;C07D237/10;C07D239/28;C07D241/14;C07D257/04;C07D263/16;C07D277/32;C07D285/15;C07D307/60;C07D333/26;C07D401/12;C07D401/14;C07D403/12;C07D403/14;C07D405/12;C07D405/14;C07D409/12;C07D409/14;C07D413/12;C07D413/14;C07D417/12;C07D417/14;A61K317/395;

  • 国家 IL

  • 入库时间 2022-08-22 00:45:03

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号